Welcome to our dedicated page for Ultragenyx Pharm news (Ticker: RARE), a resource for investors and traders seeking the latest updates and insights on Ultragenyx Pharm stock.
Ultragenyx Pharmaceutical Inc. develops and commercializes therapies for serious rare and ultra-rare genetic diseases. Company news commonly covers revenue from approved medicines such as Crysvita, Dojolvi, and Mepsevii, financial guidance, and updates to a portfolio of approved therapies and product candidates for diseases with high unmet medical need and clear biology.
Recurring developments include FDA interactions and clinical data for investigational programs such as UX111 for Sanfilippo syndrome type A, GTX-102 for Angelman syndrome, UX016 for GNE myopathy, and AAV gene therapy candidates for rare metabolic disorders. Updates also include healthcare conference participation, employment inducement equity grants under Nasdaq rules, and corporate restructuring or expense-management actions when disclosed.
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) announced the grant of stock options and restricted stock units to ten newly hired non-executive officers. A total of 7,130 stock options and 5,885 restricted stock units were awarded under the Ultragenyx Employment Inducement Plan, approved by the compensation committee of the board of directors. The stock options have a ten-year term with an exercise price of $40.22, corresponding to the closing stock price on the grant date of March 16, 2023. Both stock options and restricted units will vest over four years, promoting retention among new employees dedicated to addressing rare diseases.
Ultragenyx Pharmaceutical has announced the promotion of Dr. Eric Crombez to chief medical officer and executive vice president, effective May 1, 2023. He succeeds Dr. Camille Bedrosian, who will transition to a strategic advisory role. Dr. Crombez, who has been pivotal in developing clinical programs for rare genetic disorders, previously served as CMO for gene therapy and inborn errors of metabolism. Under his leadership, the company aims to enhance its pipeline focused on treatments for rare diseases. Ultragenyx is committed to delivering therapies with high unmet needs efficiently and effectively.
Ultragenyx Pharmaceutical (NASDAQ: RARE) announced that CEO Emil D. Kakkis will speak at the Orphan Neuro Panel during Cowen's 43rd Annual Health Care Conference on March 7, 2023, at 10:30 a.m. ET. This event highlights the company's commitment to developing therapies for rare genetic diseases. The live and archived webcast will be available on the company's website for 30 days following the event. Ultragenyx focuses on creating innovative products to meet urgent medical needs with no existing treatments available, led by a team skilled in rare disease therapeutics.
Ultragenyx Pharmaceutical reported a total revenue of $363.3 million for 2022, marking a growth from $351.4 million in 2021. Key drivers included Crysvita, contributing $279.4 million, and Dojolvi with $55.6 million. For 2023, the company projects total revenue between $425 million and $450 million, with Crysvita revenue expected to reach $325 million to $340 million. Despite strong revenue growth, Ultragenyx reported a net loss of $707.4 million for 2022, an increase from $454 million in 2021. The company also holds a healthy cash balance of $896.7 million as of December 31, 2022.
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) announced a conference call on February 16, 2023, at 5:00 p.m. ET, to discuss its financial results for Q4 and the full year ending December 31, 2022. This call will provide insights into the company's performance in developing therapies for rare genetic diseases. Interested participants can access the live call via the company's website, and a replay will be available for one year. Ultragenyx focuses on novel therapies to meet the high unmet medical needs of patients with rare diseases.
Ultragenyx Pharmaceutical reported preliminary total product revenue for 2022 between $352 million to $356 million, with Crysvita revenue estimated at $257 million to $258 million and Dojolvi revenue at $55 million to $56 million. For 2023, the company guides total revenue of $425 million to $450 million, driven by Crysvita and Dojolvi. The cash balance at year-end 2022 was approximately $900 million. Expectations for net cash used in operations in 2023 are under $400 million. The company emphasizes advancements in its pipeline and a focus on reducing cash spending.
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) announced that CEO Emil D. Kakkis will present at the 41st Annual J.P. Morgan Healthcare Conference on January 10, 2023, at 12:45 PM ET. The presentation will focus on the company's commitment to developing therapies for rare genetic diseases. A live webcast will be available on their website, with a replay accessible for 30 days afterward. Ultragenyx aims for efficient drug development to provide effective treatments for patients with significant unmet medical needs.
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) announced the grant of stock options and restricted stock units to three newly hired non-executive officers, totaling 29,950 shares and 17,505 units, respectively. The awards, approved by the compensation committee, are part of the Ultragenyx Employment Inducement Plan with a grant date of December 16, 2022. Stock options vest over four years with a ten-year term at an exercise price of $45.63 per share. This move reflects Ultragenyx's commitment to attracting talent essential for developing therapies for rare diseases.
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) announced that CEO Emil D. Kakkis will present at the Piper Sandler Annual Healthcare Conference on November 29, 2022, at 10:00 AM ET in New York.
The live presentation and archived webcast will be available on the company’s website for 120 days. Ultragenyx is dedicated to developing therapies for serious rare and ultra-rare genetic diseases, focusing on unmet medical needs with a diverse portfolio of treatments.
Ultragenyx Pharmaceutical (NASDAQ: RARE) has approved stock options and restricted stock units for a newly hired non-executive officer. The grant, dated November 16, 2022, includes 5,380 stock options and 5,000 restricted stock units. The stock options have a ten-year term with an exercise price of $35.22. Both the stock options and restricted stock units vest over four years, contingent on continuous employment. This decision aligns with Nasdaq Listing Rule 5635(c)(4) and reflects the company’s commitment to attracting talent in the biopharmaceutical sector focused on rare diseases.